Lilly's Big Bet on Gene Editing: $1.3 Billion Deal
Kilder
- Genengnews: Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News
- Nature: The next generation of immunotherapies for lung cancers - Nature
- Statnews: Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion - statnews.com
- Fiercebiotech: Eli Lilly pays $1B upfront to buy gene editing partner Verve Therapeutics - Fierce Biotech
- Biospace: Lilly Validates Gene Editing Space With $1.3B Verve Buy, But Analysts Are Skeptical - BioSpace
- Bioworld: In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.